Today’s AI Top Pick: PODD

7/23/2026 · Turnaround screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Measured daily model accuracy · PODD82%218 resolved forecasts · 45d window · verify →

Today's pick · TurnaroundPODDBUY NOW8.9 / 107/23/2026

Insulet (PODD) is the cleanest fundamentals-plus-tape setup in the pool right now. On the fundamentals side it clears every screen with room to spare: ROE 23%, profit margin 10.44%, salesYoY 31.93%, epsNextY 24.34%, forward PE 19.73, PEG 0.74, recom 1.48, and a fundamental_score of 8 — this is a genuinely high-quality medtech that has been beaten down 44% YTD/44% on 1Y (perfYear -44.35%), which is exactly the mispricing the turnaround lens is trying to catch. The tape confirms without chasing. All four timeframes point up on forecasts: 1h fc_mid +9.05% / fc_long +10.51%, 4h fc_mid +40.36% / fc_long +62.44%, 1d fc_short +41.5% / fc_mid +66.03% / fc_long +61.04%, and even the punished 1wk shows fc_short +16.62% / fc_mid +39.48% / fc_long +59.0%. Near-term bullish is 1.0 and bullish_prob is 1.0. Crucially, PODD is NOT extended — position_in_21bar_range is 13.88% on 1h, 35.77% on 4h, 46.62% on 1d, and only 13.64% on 1wk, with a weekly drawdown of -33.55%. That is the textbook 'coiled at the bottom of the range with all forecasts pointing higher' shape. The news file is clean and slightly positive: Q2 2026 earnings preview coverage, and a 'Quality Affordable Growth Stock With Strong Earnings Momentum' writeup on 7/16 — no guidance cut, no legal/regulatory hit, no dilution, no short-seller report. Compare that to FUTU (DOJ probe + class actions), HSAI (PE 266 / PS 34.57 stretched despite good tape), MNDY (20% layoffs, restructuring turmoil), FRSH & TOST (forecasts actually decay into the long horizon), and CELH (near_term_bullish 0.2, sitting at 96% of the 1h range = chasing). PODD gives you the strongest joint fundamentals + multi-TF forecast alignment + clean headlines in the pool. Today is the entry because you're buying an $11B durable-growth medtech at the low end of its 21-bar weekly range with an earnings catalyst approaching, and every forecast horizon is bullish while price hasn't yet extended — the asymmetric risk/reward compresses if you wait for the 1d forecast (+41.5% short) to start playing out.

Entry zone

$154.50 – $159.00 (scale in around current $157.50; add on any dip to the weekly low band near $150)

Stop loss

$146.50 (below the -8% 1d 21bar drawdown level; a close under would invalidate the reversal thesis)

First target

$180 (+14%, aligns with 4h fc_short/mid magnitude and reclaim of prior range)

Longer target

$215 – $230 (+37–46%, matches 1d/4h fc_long +61–62% off a lower entry and normalization from the -44% YTD drawdown)

Risks

Q2 2026 earnings due imminently — a guide-down could snap the -33.55% weekly drawdown into a fresh leg lower
Short float 7.04% and instOwn reported at 104.9% suggests crowded institutional positioning; any hedge fund exit accelerates downside
Healthcare/medtech reimbursement or GLP-1 competitive-narrative headlines could reprice the multiple (fwdPe 19.73 already assumes growth persists)
1wk fc_short is only +16.62% while the stock is -33.55% off 21-bar high — recovery may be choppy, not linear
Debt/Equity 0.73 is manageable but not trivial for a company with 10.44% profit margin if growth decelerates

Honorable mentions

BILIMulti-TF alignment (1h/4h/1d all rising, 1d fc_short +41.99%, fc_mid +45.24%), position 53% on 1d but only 13.59% on 1wk, PEG 0.53, fwdPe 13.43, recom 1.30, targetUpsidePct 62.3, and a bullish 2Q26 preview headline — the cheapest way to play the same setup as PODD.

CALX1d fc_short +34.31%, fc_mid +47.02%, fc_long +44.28%, near_term_bullish 0.8, position 12.33% on 1d and 1.8% on 1wk (deeply oversold), recom 1.22, Northland upgrade + 'Could Be 46% Undervalued' headline on 7/23 — strong catalyst-backed turnaround but smaller cap ($2.29B) so sizing matters.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	PODD	BUY NOW	8.9	Fund score 8, all-TF forecasts up (1d fc_mid +66%), position 13.6% of 1wk range, clean news — cleanest setup in the pool.
2	BILI	BUY NOW	8.3	1d fc_short +42%, PEG 0.53, fwdPe 13.4, positive 2Q preview — best value+tape combo behind PODD.
3	CALX	BUY NOW	8.0	Deeply oversold (1wk pos 1.8%), 1d fc_mid +47%, fresh Northland upgrade + undervalued call.
4	ORCL	BUY NOW	7.6	ROE 54%, fwdPe 11.5, 1d fc_mid +39%, targetUpside 99.4% — mega-cap turnaround but 1wk fc slightly negative.
5	SRAD	BUY PULLBACK	7.3	1d fc_mid +41%, near_term_bullish 1.0, but 1h fc_long -8.7% suggests immediate wobble; buy dip.
6	HSAI	BUY PULLBACK	7.2	Forecasts huge (4h fc_mid +56%) but PE 266 / PS 34.57 stretched; stock split adds volatility.
7	TMDX	BUY NOW	7.0	1d fc_mid +60%, ROE 45%, but short float 23.68% and a recent Evercore PT cut cap conviction.
8	STEP	BUY NOW	6.7	All TF forecasts up (1d fc_mid +37%), fwdPe 12.3, salesYoY 69.9%; negative margins the caveat.
9	NOW	BUY PULLBACK	6.5	1d fc_long +48.7% and clean AI partnership news, but 4h forecasts negative and 1h at 84% of range.
10	MLCO	BUY NOW	6.4	PEG 0.35, fwdPe 7.95, 1wk fc_long +54%, but small cap ($2.1B) and macau macro-sensitive.
11	GRAB	BUY PULLBACK	6.3	1d fc_mid +35%, PEG 0.39, but CEO share sale headline and 1h/4h positions in low single digits — wait for base.
12	KKR	BUY NOW	6.1	PEG 0.64, fwdPe 13, 1d fc_mid +12.4%, active deal flow (Allyntra/Qiagen); moderate forecast magnitudes.
13	ONON	BUY NOW	5.9	PEG 0.43, salesYoY 36%, near_term_bullish 0.8; forecasts modest (~7–14%) so it's steady not explosive.
14	APO	BUY PULLBACK	5.8	Fund score 8, HSBC initiates Buy, but 1h/4h at 100% of range and 1wk fc_long -8.35% — don't chase.
15	CHWY	BUY PULLBACK	5.6	1d fc_mid +49.6%, ROE 63.8%, but position 89.6% on 4h suggests immediate mean reversion risk.
16	SE	WAIT	5.4	1d fc up but 1h fc_long -12.24%; position 73% on 1d + 82% on 1wk means already ran.
17	MNDY	BUY PULLBACK	5.3	Weekly fc_long +179% is an outlier, and 20% layoffs create restructuring risk — extreme numbers need discount.
18	HLI	BUY PULLBACK	5.2	1d fc_mid +23.6%, recom 2.0, KBW PT cut; earnings decline expected — modest edge.
19	ARES	WAIT	5.0	1wk fc_long -9.5% and Oppenheimer PT cut; fund score only 5.5.
20	SPOT	WAIT	4.8	1wk fc all negative (-19% to -24%), Benchmark PT cut — tape says wait.
21	UBER	WAIT	4.7	PEG 3.03, 1wk fc essentially flat, layoff headline mixed signal — screen pass but no juice.
22	WING	BUY PULLBACK	4.6	1d fc_mid +71% eye-catching but stock -42% YTD with soft comps — earnings next week is binary.
23	MELI	WAIT	4.5	PEG 1.25, fwdPe 31.9, expected_return only 20% — least dislocation in the pool.
24	CELH	BUY PULLBACK	4.3	Fund score 8 but near_term_bullish 0.2 and 1h pos 96% — chasing risk right now.
25	TOST	WAIT	4.0	1h fc_short -18.6%, 4h fc_mid -10.6% — forecasts decay against you across timeframes.
26	QXO	WAIT	4.0	SalesYoY 15,198% (M&A distortion), negative margins, fund score 4.75 — too speculative.
27	FRSH	AVOID	3.7	Bullish_prob only 0.6, 1h fc_long -9%, 4h fc_long -10%, 1wk fc negative — deteriorating setup.
28	DASH	WAIT	3.7	fwdPe 39.8, PEG 0.81 optically ok but tape data incomplete and near_term_bullish 0.8 not enough to overpay.
29	FICO	WAIT	3.5	PS 12.56, 1h forecasts negative, tape data cut — pricey and unconfirmed.
30	FUTU	AVOID	3.0	DOJ probe + class-action headline on 7/3 plus 1wk fc_long -20.9% — landmine despite great fundamentals.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord